1. Scrip
  2. >>Therapy Areas

Merck Serono DreaMS of securing MS franchise with Ono deal

 
• By Pial Ganguli

Merck Serono has signed two collaboration agreements with Japan's Ono Pharmaceutical with a view to strengthening two of its franchises, those covering multiple sclerosis (MS) and cancer.

Merck Serono has signed two collaboration agreements with Japan's Ono Pharmaceutical with a view to strengthening two of its franchises, those covering multiple sclerosis (MS) and cancer.

The first agreement grants Merck worldwide exclusive licence rights for the development and commercialisation of an oral investigational sphingosine-1-phosphate (S1P)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.